Article
Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage vB_KpnMVAC13 against clinical isolates of klebsiella pneumoniae
Author/s | Pacios, Olga
Fernández-García, Laura Bleriot, Inés Blasco, Lucía González-Bardanca, Mónica Pascual Hernández, Álvaro Tomasa, María |
Department | Universidad de Sevilla. Departamento de Microbiología |
Publication Date | 2021 |
Deposit Date | 2022-10-13 |
Published in |
|
Abstract | Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting ... Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting imipenem-resistant and persister strains of K. pneumoniae by repurposing the anticancer drug mitomycin C as an antimicrobial agent and by combining the drug and the conventional antibiotic imipenem with the lytic phage vB_KpnM-VAC13. Several clinical K. pneumoniae isolates were characterized, and an imipenem-resistant isolate (harboring OXA-245 β-lactamase) and a persister isolate were selected for study. The mitomycin C and imipenem MICs for both isolates were determined by the broth microdilution method. Time-kill curve data were obtained by optical density at 600 nm (OD600) measurement and CFU enumeration in the presence of each drug alone and with the phage. The frequency of occurrence of mutants resistant to each drug and the combinations was also calculated, and the efficacy of the combination treatments was evaluated using an in vivo infection model (Galleria mellonella). The lytic phage vB_KpnM-VAC13 and mitomycin C had synergistic effects on imipenem-resistant and persister isolates, both in vitro and in vivo. The phage-imipenem combination successfully killed the persisters but not the imipenem-resistant isolate harboring OXA-245 β-lactamase. Interestingly, the combinations decreased the emergence of in vitro resistant mutants of both isolates. Combinations of the lytic phage vB_KpnM-VAC13 with mitomycin C and imipenem were effective against the persister K. pneumoniae isolate. The lytic phage-mitomycin C combination was also effective against imipenem-resistant K. pneumoniae strains harboring OXA-245 β-lactamase |
Citation | Pacios, O., Fernández-García, L., Bleriot, I., Blasco, L., González-Bardanca, M., Pascual Hernández, Á. y Tomasa, M. (2021). Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage vB_KpnMVAC13 against clinical isolates of klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 65 (9), 1-11. https://doi.org/10.1128/AAC.00900-21. |
This item appears in the following collection(s)
This document is protected by intellectual and industrial property rights. Without prejudice to existing legal exemptions, its reproduction, distribution, public communication or transformation is prohibited without the authorization of the rights holder, unless otherwise indicated.